,54 A recent small clinical trial of high-dose oral l-serine supplementation in patients with HSN1 did not meet the primary endpoint but did show significant improvement in the Charcot-Marie-Tooth neuropathy score (version 2) with minimal side effects.54 The gene discussed is SPTLC1; the disease is Charcot-Marie-Tooth disease, axonal, type 2FF.